Company Overview and News

60
Cboe Global May ADV Soft, Global FX Matched Solid, Shares Up

2018-06-08 zacks
Cboe Global Markets, Inc. (CBOE - Free Report) reported average daily volume (ADV) of nearly 7 million for May 2018. Though ADV declined 5.3% year over year, shares of the company gained nearly 3.6% in the last couple of trading sessions. Total contracts for the month were 152.9 million, slipping nearly 5.3% year over year. Of this, options contracts declined 4.7% year over year to 147.6 million while futures contracts fell 4.
7018 CME UNP MKTX FCELB ICE FCEL

46
CME Group's (CME) May Volume Figures Strong, Shares Rise

2018-06-06 zacks
CME Group Inc.’s (CME - Free Report) average daily volume (ADV) of 20.1 million contracts per day for May 2018 improved 22% year over year. A record daily volume of 51.9 million contracts traded on May 29 largely drove this upside. Shares gained 1.7% in the last two trading years reflecting investor optimism. During last month, Options volume expanded 5% year over year to average 3.6 million contracts while interest rate volume surged 30% year over year and averaged at 11.
NDAQ 7018 CME MKTX ICE

44
Nasdaq (NDAQ) Reports Mixed Volumes for May, Shares Rise

2018-06-06 zacks
Nasdaq, Inc. (NDAQ - Free Report) has reported mixed volumes for May 2018. While the U.S. equity options volume increased 2.2% year over year to 140 million contracts, European options and futures volumes decreased 18.3% year over year to 7.6 million contracts. Shares inched up 0.2% in the last trading session. Under its cash equities, Nasdaq’s U.S. matched equity volume in the month totaled 27.4 million shares, up 1.
7018 CME MKTX ICE

2
MarketAxess to Participate in William Blair 2018 Growth Stock Conference

2018-06-05 globenewswire
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- MarketAxess Holdings Inc. (Nasdaq:MKTX), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, today announced that Tony DeLise, Chief Financial Officer, is scheduled to present at the William Blair 2018 Growth Stock Conference on June 12, 2018 at 9:30am CST.
MKTX

2
MarketAxess Announces Monthly Volume Statistics for May 2018

2018-06-04 globenewswire
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- MarketAxess Holdings Inc. (Nasdaq:MKTX), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, today announced total monthly trading volume for May 2018 of $141.2 billion, consisting of $75.1 billion in U.S. high-grade volume, $61.8 billion in other credit volume, and $4.
MKTX

3
MKTX / MarketAxess Holdings, Inc. / BAILLIE GIFFORD & CO - null (Passive Investment)

2018-06-04 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3) MARKETAXESS HOLDINGS INC. ----------------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------------- (Title of Class of Securities) 57060D108 ----------------------------------------------------------------------- (CUSIP Number
MKTX

4
MKTX / MarketAxess Holdings, Inc. / BAILLIE GIFFORD & CO - null (Passive Investment)

2018-06-04 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3) MARKETAXESS HOLDINGS INC. ----------------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------------- (Title of Class of Securities) 57060D108 ----------------------------------------------------------------------- (CUSIP Number
MKTX

104
Cboe Global (CBOE) Beats on Q1 Earnings, Revises Guidance

2018-05-07 zacks
Cboe Global Markets, Inc.’s (CBOE - Free Report) first-quarter 2018 adjusted earnings of $1.38 per share beat the Zacks Consensus Estimate of $1.27 by 8.7%. Moreover, the bottom line improved nearly 47% year over year.
CBOE 7018 CME UNP ODP MKTX RDUS

58
Intercontinental Exchange (ICE) Q1 Earnings Top, Rise Y/Y

2018-05-03 zacks
Intercontinental Exchange, Inc. (ICE - Free Report) reported first-quarter 2018 adjusted earnings per share of 90 cents, beating the Zacks Consensus Estimate of 88 cents by 2.3%. Also, the bottom line improved 21.6% on a year-over-year basis.
7018 CME RSG MKTX AVP ICE

2
MarketAxess Announces Monthly Volume Statistics for April 2018

2018-05-02 globenewswire
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- MarketAxess Holdings Inc. (Nasdaq:MKTX), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, today announced total monthly trading volume for April 2018 of $131.8 billion, consisting of $73.6 billion in U.S. high-grade volume, $54.4 billion in other credit volume, and $3.
MKTX

2
MKTX / MarketAxess Holdings, Inc. 10-Q (Quarterly Report)

2018-04-27 sec.gov
mktx-10q_20180331.htm
MKTX

48
CME Group (CME) Q1 Earnings Beat, Revenues Lag Estimates

2018-04-26 zacks
CME Group Inc. (CME - Free Report) reported first-quarter 2018 adjusted earnings per share of $1.86, beating the Zacks Consensus Estimate of $1.85 by 0.5%. Moreover, the bottom line soared 52.5% year over year.
7018 CME MKTX ICE KO UTX

5
MarketAxess (MKTX) Q1 Earnings Top on Higher Trading Volumes

2018-04-26 zacks
MarketAxess Holdings Inc.’s (MKTX - Free Report) first-quarter 2018 earnings per share of $1.27 beat the Zacks Consensus Estimate by 4.1% and grew 14% year over year.
MKTX KO

2
MarketAxess Holdings (MKTX) CEO Rick McVey on Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
MarketAxess Holdings, Inc. (NASDAQ:MKTX) Q1 2018 Results Earnings Conference Call April 25, 2018 10:00 AM ET
MKTX

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 57060D108